Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.65 |
| ▸ | PGR | P06401 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL6 | P05231 | 1/20 | 0.65 |
| ▸ | GLUL | P15104 | 1/20 | 0.65 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1929804 | 0.97 | NR3C1 (0.64) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Phosphoric Acid SCHEMBL5501494 | 0.95 | NR3C1 (0.67) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL13270299 | 0.95 | HIF1A (0.72) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL1512721 | 0.95 | HIF1A (0.72) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL2299293 | 0.95 | HIF1A (0.72) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| SCHEMBL719929 | 0.94 | HIF1A (0.70) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL40948 | 0.92 | HIF1A (0.64) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL1477515 | 0.92 | HIF1A (0.64) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7600416 | 0.90 | HIF1A (0.66) | NR3C1HIF1AHSD17B10PGRCYP3A4 | |
| Succinic Acid SCHEMBL7096415 | 0.90 | HIF1A (0.63) | NR3C1HIF1AHSD17B10PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | DOMPE' FARMACEUTICI SPA (IT) | 2023-04-06 | — | — | US | claimed |
| EP-4106738-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | claimed |
| US-20220096498-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2022-03-31 | — | — | US | claimed |
| CN-113795246-A | Injectable sustained release formulation for the treatment of joint pain and inflammation | 福多兹制药公司 | 2021-12-14 | — | — | CN | claimed |
| WO-2020227353-A1 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | FORDOZ PHARMA CORP. (US) | 2020-11-12 | — | — | WO | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| US-12589102-B2 | Injectable sustained-release formulations for treatment of joint pain and inflammation | FORDOZ PHARMA CORP. (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025264734-A1 | COLLAGEN MACROPEPTIDE PREPARATIONS AND USES THEREOF | BIOVENTUS LLC (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250381250-A1 | COLLAGEN MACROPEPTIDE PREPARATIONS AND USES THEREOF | BIOVENTUS LLC (US) | 2025-12-18 | — | — | US | disclosed |
| CN-113795246-B | Injectable sustained release formulation for the treatment of joint pain and inflammation | 福多兹制药公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-115484943-B | Combination of CXCL8 (interleukin-8) activity inhibitor and corticosteroid, pharmaceutical composition and use thereof | 导博药物公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | DOMPE' FARMACEUTICI SPA (IT) | 2023-04-06 | — | — | US | disclosed |
| EP-4106738-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Dompe' Farmaceutici SpA (IT) | 2022-12-28 | — | — | EP | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
| US-5326761-A | Suspension; sustained release | MERCK SHARP & DOHME-CHIBRET (FR) | 1994-07-05 | — | — | US | disclosed |
| EP-0437368-B1 | Fluid ophthalmic composition based on lipid microparticles containing at least one active principle | MERCK SHARP & DOHME (FR) | 1994-03-02 | — | — | EP | disclosed |
| EP-0437368-A1 | Fluid ophthalmic composition based on lipid microparticles containing at least one active principle | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108050-A1 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | CXCL8, CCR8, MMP8 | NR3C1 91/4885HIF1A 2536/4885HSD17B10 1306/4885 |
| US-12589102-B2 | Injectable sustained-release formulations for treatment of joint pain and inflammation | IL1B, TNF, MIF | NR3C1 25/4885HIF1A 1158/4885HSD17B10 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.